Treatment Information

Back

Liver Cancer treatment details. Biologic therapy.

Chinese University of Hong Kong, Hong Kong, China.

Survival: monthsCountry:China
Toxiciy Grade:5City/State/Province:Hong Kong
Treatments:Biologic therapyHospital:Chinese University of Hong Kong
Drugs:Journal:Link
Date:Sep 2012

Description:

Patients:
This phase 2 study involved 42 hepatocellular carcinoma patients. The median patient age was 57.5 years and 90% were male.

Treatment:
Patients were treated with the biologic therapy agent belinostat, which is an inhibitor of a protein involved in DNA replication and cancer cell growth.

Toxicities:
There was one reported death due to unknown causes reported for this study. Grade 4 anemia and abdominal pain, and grade 3 vomiting were also reported.

Results:
The median overall survival was 6.6 months.

Support:
This study was supported by TopoTarget, makers of belinostat.

Correspondence: Dr. Winnie Yeo; email: [email protected]



Back